Final analysis shows ADSTILADRIN was well-tolerated with no new study drug-related adverse events — <4% of patients experienced Grade 3…
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal…
Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies…
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a…
Results of a Phase 3 study show durable complete response in evaluation of high-grade recurrence-free survival, cystectomy-free survival, and overall…
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility…
Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium…
Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy…
Ferring Pharmaceuticals’ Fertility Out Loud Docuseries follows four U.S.-based couples as they face their unique fertility journeys head-on Episode one…
36-month follow-up data from the Phase 3 study demonstrate one-quarter of patients with high-risk, BCG-unresponsive NMIBC remained free of high-grade…